No Detail Found!

In Vitro Susceptibility of Mrsa Clinical Isolates to Ceftaroline.

Author(s)
Muhammad Aurangzeb 72 Medical Battalion Pano Aqil Sindh, Pakistan,
Raja Kamran Afzal Combined Military Hospital Peshawar, Pakistan
Muhammad Abid Combined Military Hospital Peshawar, Pakistan
Aamir Hussain Combined Military Hospital Peshawar, Pakistan
Fauzia Aitazaz Azad Jammu Kashmir Medical College, Muzaffarabad, Pakistan
Rozina Khaliq Azad Jammu Kashmir Medical College, Muzaffarabad, Pakistan
Abstract
Objective: To determine the in vitro susceptibility of MRSA clinical isolates to ceftaroline, using interpretation of zones of inhibition by disk diffusion method. Study Design: Descriptive cross sectional. Place and Duration of Study: The study was carried out at the Department of Microbiology, Combined Military Hospital Peshawar, from Jan to Dec 2014. Material and Methods: To carry out this descriptive cross sectional study, clinical specimens were obtained from indoor and outdoor patients of Combined Military Hospital Peshawar. All the isolates of MRSA cultured with CLSI guidelines and identified with standard microbiological procedures, from clinical specimens of pus, body fluid, urine, tissue and blood were included in the study. The antimicrobial susceptibility pattern of ceftaroline was determined according to CLSI guidelines. The data was analyzed in SPSS (version 19) software. Results: Out of a total 190 MRSA isolates, 183 (96.3%) were susceptible to ceftaroline in vitro, whereas 5 (2.6%) were resistant and 2 (1.1%) were intermediate in their response to ceftaroline. Conclusion: Ceftaroline can be used effectively against infections caused by MRSA as it has shown very high in vitro activity against MRSA strains of clinical origin.
Publication Details
Page(s) 265-268
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 68, Issue: 2, Year: 2018

Request the full text from PASTIC

References
RaygadaJL,LevineDP, 2009.Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community,Am Health Drug Benefits 2 86 -95
IdreesF,JabeenK,KhanMS,ZafarA, 2009.Antimicrobial resistance profile of methicillin resistant Staphylococcus aureus from skin and soft tissue isolates,J Pak Med Assoc 59 266 -9
WangZ,CaoB,LiuYM,GuL,WangC, 2009.Investigation of the prevalence of patients co-colonized or infected with methicillinresistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study,Chin Med J 122 1283 -8
RashidZ,FarzanaK,SattarA,MurtazaG, 2012.Prevalence of nasal Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in hospital personnel and associated risk factors,Acta Pol Pharm 69 985 -91
ShresthaB,PokhrelB,MohapatraT., 2009.Antibiotic susceptibility pattern of nosocomial isolates of Staphylococcus aureus in a tertiary care hospital,Nepal. J Nepal Med Assoc 48 234 -8
CastanheiraM,SaderHS,FarrellDJ,MendesRE,JonesRN, 2012.Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types,Antimicrob Agents Chemother 56 4779 -85
KollefMH, 2009.New antimicrobial agents for methicillin-resistant 'Staphylococcus aureus',Crit Care Resusc 11 282 -6
2014.M100-S24 performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement;, -
LaudanoJB, 2011.Ceftaroline fosamil: A new broad-spectrum cephalosporin,J Antimicrob Chemother 66 11 -18
FarrellDJ,CastanheiraM,MendesRE,SaderHS,JonesRN, 2012.Clinical infectious diseases, 55 206 -14
SantosPD,DavisA,JandourekA,SmithA,David FH, 2013.Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience,J Antimicrob Chemother 25 341 -46
FriedlandD,EckburgP,JandourekA,HanS,ThyeD,CritchleyI., 2010.Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia,Am J Respir Crit Care Med 181 5481 -
JacquelineC,CaillonJ,MabecqueLV,MiègevilleAF,HamelA,BugnonD, 2007.In vivo efficacy of ceftaroline (PPI-0903), A new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model,Antimicrob Agents Chemother 51 3397 -400
JacquelineC,CaillonJ,Le MabecqueV,MiegevilleAF,GeY,BiekD, 2009.In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus, cephalosporin, ceftaroline, against vancomycin-susceptible and-resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin,Antimicrob Agents Chemother 53 5300 -2
JacquelineC,CaillonJ,BatardE,Le MabecqueV,AmadorG,GeY, 2010.Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model,J Antimicrob Chemother 65 2264 -5
JacquelineC,AmadorG,CaillonJ,Le MabecqueV,BatardE,MiègevilleAF, 2010.Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis,J Antimicrob Chemother 65 1749 -52
JonesRN,FlammRK,SaderHS,StilwellMG, 2013.Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate beta-lactam markers to predict ceftaroline activity against clinically indicated species,Diagn Microbiol Infect Dis 75 89 -93
ClarkMP,AppelbaumPC,Kosowska-ShickK, 2011.Multistep resistance development studies of ceftaroline in gram-positive and negative bacteria,Antimicrob Agents Chemother 55 2344 -51
JacobsMR,GoodCE,WindauAR,BajaksouzianS,BiekD,CritchleyIA, 2010.Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States,Antimicrob Agents Chemother 54 2716 -9
BradleyJS,ByingtonCL,ShahSS,AlversonB,CarterER,HarrisonC, 2011.The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America,Clin Infect Dis 53 25 -76
0

Citations

0

Downloads

68

Views